**: Yaozhi.com***
Photo.com.
On the road of pharmaceutical research and development, every step is full of challenges and opportunities. In order to help researchers explore more efficiently, Yaozhi.com has joined hands with Shanghai Jiaotong University and Tianhu Technology to bring a new solutionAI druggability (ADMET)** platform
Powerful, precise
This AI druggability (ADMET)** platform is a powerful tool for the druggability analysis of compounds. It enables the correlation of key parameters related to compound structure and druggability, including:Absorption, distribution, metabolism, excretion, and toxicityand hundreds of druggability parameters. Based on the state-of-the-art graph neural network architecture and multiple molecular descriptors, our platform creates a model with independent intellectual property rights to ensure accuracy and reliability.
Globally leading, backed by data
In order to ensure the accuracy and efficiency of the drug, we have invested a lot of manpower and resources to sort out tens of millions of data on various indicators of drug molecule druggability. On top of that, we builtMore than 160 parametersmodel, and validated using real-world data from approved drugs worldwide. This provides strong support for drug development and makes our platform the world's leading commercialization software with the properties of AI**ADMET.
Widely used to help breakthroughs
Whether you are in the screening stage of hit compounds, or the optimization of lead compounds, preclinical development, clinical trials and other stages, the AI druggability (ADMET)** platform can provide you with strong data support.
Early screening: Rapid screening of potential hit compounds to provide strong support for subsequent drug research and development.
Lead evaluation and optimization: Comprehensively and accurately evaluate the ADMET properties of active substances, screen out lead compounds with good druggability, and assist medicinal chemists in design and optimization.
Improve clinical development success: By optimizing and improving lead compounds, the success rate of subsequent clinical development can be improved, which provides an important basis for decision-making in the drug development process.
Safety evaluation and adverse reactions**: To provide reference data for new drugs in human safety evaluation, ** potential adverse reactions of compounds, and guide the formulation of follow-up trial research directions and strategies.
Experience now and open a new chapter in new drug research and development!
The future is here, are you ready?
We look forward to cooperating with you, let us work together to open a new chapter in pharmaceutical research and development!
Disclaimer: This content is only used for information dissemination in the pharmaceutical industry, and is the author's independent point of view, and does not represent the position of PharmA.X. If you need it, be sure to give credit to the author of the article and**. If you have any objections or complaints about this article, please contact maxuelian@yaozhcom。